MY180106A - Method of reducing exercise-induced joint pain in non-arthritic mammals - Google Patents

Method of reducing exercise-induced joint pain in non-arthritic mammals

Info

Publication number
MY180106A
MY180106A MYPI2014001885A MYPI2014001885A MY180106A MY 180106 A MY180106 A MY 180106A MY PI2014001885 A MYPI2014001885 A MY PI2014001885A MY PI2014001885 A MYPI2014001885 A MY PI2014001885A MY 180106 A MY180106 A MY 180106A
Authority
MY
Malaysia
Prior art keywords
joint pain
induced joint
reducing exercise
mammals
arthritic
Prior art date
Application number
MYPI2014001885A
Other languages
English (en)
Inventor
Paul Dijkstra
Francis C Lau
James Lugo
Zainulabedin M Saiyed
Original Assignee
Interhealth Nutraceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interhealth Nutraceuticals Incorporated filed Critical Interhealth Nutraceuticals Incorporated
Publication of MY180106A publication Critical patent/MY180106A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI2014001885A 2013-10-24 2014-01-13 Method of reducing exercise-induced joint pain in non-arthritic mammals MY180106A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361895332P 2013-10-24 2013-10-24

Publications (1)

Publication Number Publication Date
MY180106A true MY180106A (en) 2020-11-23

Family

ID=51610711

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014001885A MY180106A (en) 2013-10-24 2014-01-13 Method of reducing exercise-induced joint pain in non-arthritic mammals

Country Status (14)

Country Link
US (1) US9066926B2 (cg-RX-API-DMAC7.html)
KR (1) KR101664290B1 (cg-RX-API-DMAC7.html)
AR (1) AR095104A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014202041B8 (cg-RX-API-DMAC7.html)
BR (1) BR112014011741A2 (cg-RX-API-DMAC7.html)
CA (1) CA2846644C (cg-RX-API-DMAC7.html)
CL (1) CL2014001281A1 (cg-RX-API-DMAC7.html)
CO (1) CO7020846A2 (cg-RX-API-DMAC7.html)
IN (1) IN2014DE00193A (cg-RX-API-DMAC7.html)
MX (1) MX347669B (cg-RX-API-DMAC7.html)
MY (1) MY180106A (cg-RX-API-DMAC7.html)
PH (1) PH12014501453A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201403524RA (cg-RX-API-DMAC7.html)
WO (1) WO2015060888A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226513B2 (en) 2015-01-09 2019-03-12 Mark Terrell Smith Method and composition to prevent or improve symptoms of musculoskeletal distress degeneration
WO2018052695A1 (en) * 2016-09-16 2018-03-22 Boston Scientific Neuromodulation Corporation System for pain management using heart sounds
EP3932298A1 (en) 2016-09-27 2022-01-05 Boston Scientific Neuromodulation Corporation System for pain management using objective pain measure
US10610688B2 (en) 2016-09-27 2020-04-07 Boston Scientific Neuromodulation Corporation Systems and methods for closed-loop pain management
US11793217B1 (en) 2016-10-04 2023-10-24 Lonza Greenwood Llc Method of manufacture and pasteurization of products containing undenatured collagen
KR102556540B1 (ko) * 2016-10-12 2023-07-18 어드밴스드 바이오매트릭스, 인코포레이티드 천연 세포외기질 분자로 제조된 3차원(3-d) 프린팅 잉크
EP4643934A3 (en) 2016-10-25 2025-11-26 Boston Scientific Neuromodulation Corporation System for pain management using baroreflex sensitivity
EP3568861B1 (en) 2017-01-11 2024-12-11 Boston Scientific Neuromodulation Corporation Pain management based on emotional expression measurements
US10631777B2 (en) 2017-01-11 2020-04-28 Boston Scientific Neuromodulation Corporation Pain management based on functional measurements
US10631776B2 (en) 2017-01-11 2020-04-28 Boston Scientific Neuromodulation Corporation Pain management based on respiration-mediated heart rates
US10729905B2 (en) 2017-01-11 2020-08-04 Boston Scientific Neuromodulation Corporation Pain management based on muscle tension measurements
EP3568069B1 (en) 2017-01-11 2021-04-28 Boston Scientific Neuromodulation Corporation Pain management based on brain activity monitoring
US11089997B2 (en) 2017-01-11 2021-08-17 Boston Scientific Neuromodulation Corporation Patient-specific calibration of pain quantification
US10960210B2 (en) 2017-02-10 2021-03-30 Boston Scientific Neuromodulation Corporation Method and apparatus for pain management with sleep detection
CN106713191B (zh) * 2017-02-28 2020-09-08 西安电子科技大学 一种多级搜索sage方法
CN107048412A (zh) * 2017-04-26 2017-08-18 北京盛美诺生物技术有限公司 一种含有ⅱ型胶原蛋白的咀嚼型产品
US10898718B2 (en) 2017-07-18 2021-01-26 Boston Scientific Neuromoduiation Corporation Sensor-based pain management systems and methods
EP3655018B1 (en) * 2017-08-21 2025-02-26 Lonza Greenwood LLC Composition and nutritional supplement made therefrom
EP3658234A1 (en) * 2017-08-31 2020-06-03 Lonza LLC Health promoting composition and methods of use supplement related applications
IT201700111939A1 (it) * 2017-10-05 2019-04-05 Jointherapeutics S R L Composizione farmaceutica per l’uso nel trattamento di stati infiammatori
BR112021000860A2 (pt) * 2018-07-16 2021-04-13 Lonza Consumer Health Inc. Suplemento de colágeno e matéria celular e método para administrar o mesmo
WO2021016665A1 (en) * 2019-07-30 2021-02-04 Atp Institute Pty Ltd A gummy composition
CA3152428A1 (en) 2019-09-30 2021-04-08 Kevin Owen Cannabinoid product for improving musculoskeletal health
US20230248808A1 (en) 2020-01-29 2023-08-10 Lonza Greenwood Llc Joint Health Composition and Use Thereof in Healthy Mammals
EP4096414A1 (en) 2020-03-03 2022-12-07 Lonza Greenwood LLC Undenatured type ii collagen in food and beverage applications and uses thereof
MX2022010859A (es) 2020-03-24 2022-11-08 Lonza Greenwood Llc Colageno tipo ii sin desnaturalizar en alimentos y golosinas para animales.
US20230256060A1 (en) * 2020-06-12 2023-08-17 Lonza Greenwood Llc Undenatured Type II Collagen as a Supplement for Improved Endurance, Lipid Metabolism, and Oxidative Stress
US20230284668A1 (en) * 2020-08-19 2023-09-14 Lonza Consumer Health Inc. Method for Improving Inflammation, Joint Health, Joint Mobility, and Joint Comfort in Healthy Mammals
CN115120618B (zh) * 2021-03-23 2024-01-26 安徽盛美诺生物技术有限公司 具有改善免疫应答作用的软骨提取物、其制备方法及其用途
EP4412637A4 (en) * 2021-11-12 2025-08-27 Lonza Greenwood Llc METHOD OF TREATING SKELETAL JOINTS, COMPOSITION AND ASSOCIATED USES
KR102771944B1 (ko) * 2023-09-25 2025-02-26 (주)온오퍼 고함량 액티브 성분을 갖는 반려동물용 츄 형태 영양제

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
EP0565678A1 (en) 1991-11-08 1993-10-20 LOFGREN NISSER, Gunilla Partially occluded contact lens for treating visual and/or brain disorder
US5637321A (en) 1994-02-28 1997-06-10 Moore; Eugene R. Method for preparing animal tissue for use in alleviating the symptoms of arthritis in mammals
US5529786A (en) 1994-02-28 1996-06-25 Moore; Eugene R. Process and product for treatment of rheumatoid arthritis
US5645851A (en) 1994-02-28 1997-07-08 Moore; Eugene R. Product for alleviating the symptons of arthritis in mammals
US6162787A (en) 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
US6372794B1 (en) * 1999-08-26 2002-04-16 Marcel E. Nimni Method for alleviating arthritis in mammals
US20020086070A1 (en) 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
US7083820B2 (en) 2000-09-29 2006-08-01 Schilling Marvin L Method for producing biologically active products
JP2003048850A (ja) 2001-06-01 2003-02-21 Nippon Meat Packers Inc 関節傷害治療剤及び機能性食品
US20060062859A1 (en) 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
FR2900155B1 (fr) * 2006-04-21 2008-06-27 Diana Naturals Sa Hydrolisat de cartilage aviaire, procede d'obtention et utilisations
US20100215731A1 (en) 2009-02-20 2010-08-26 Maastricht University Method for improving cartilage repair and/or preventing cartilage degeneration in a joint
US20110218151A1 (en) * 2010-03-04 2011-09-08 Joar Opheim Substances for promoting healthy joint function comprising omega-3 polyunsaturated fatty acids or drivatives thereof, undenatured type ii collagen and, optionally, glucosamine sulfate
CN101822684B (zh) 2010-05-27 2012-08-15 江苏江山制药有限公司 用于防治骨关节痛的复方组合制剂及其制备方法
US20120294898A1 (en) 2011-05-19 2012-11-22 Warsaw Orthopedic, Inc. Injectable dbm for soft tissue repair
CN102423487B (zh) 2011-12-23 2014-04-16 内蒙古伊利实业集团股份有限公司 一种骨关节保健组合物及其应用
CN103203012A (zh) 2012-01-12 2013-07-17 深圳市麦金利实业有限公司 关节保健品

Also Published As

Publication number Publication date
BR112014011741A2 (pt) 2017-05-30
CA2846644A1 (en) 2015-07-13
AU2014202041B8 (en) 2020-04-02
IN2014DE00193A (cg-RX-API-DMAC7.html) 2015-05-01
MX347669B (es) 2017-05-08
KR20150059132A (ko) 2015-05-29
SG11201403524RA (en) 2015-05-28
PH12014501453B1 (en) 2015-01-21
CL2014001281A1 (es) 2015-10-30
PH12014501453A1 (en) 2015-01-21
AU2014202041A1 (en) 2015-05-14
US20150119335A1 (en) 2015-04-30
AU2014202041B2 (en) 2019-11-28
AR095104A1 (es) 2015-09-30
CA2846644C (en) 2018-05-01
CO7020846A2 (es) 2014-08-11
US9066926B2 (en) 2015-06-30
KR101664290B1 (ko) 2016-10-11
MX2014002934A (es) 2015-09-21
WO2015060888A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
MY180106A (en) Method of reducing exercise-induced joint pain in non-arthritic mammals
UA110813C2 (uk) Лікування ліподистрофії
MY172578A (en) Oral dosing of glp-1 compounds
MX369067B (es) Método para reducir la producción de gas total y/o la producción de metano en un animal rumiante.
IN2014CN03887A (cg-RX-API-DMAC7.html)
MX365614B (es) Composiciones utiles para tratar trastornos relacionados con kit.
ECSP15043422A (es) Un procedimiento para aumentar la formacion de acido piroglutamico de una proteina
IN2015DN03322A (cg-RX-API-DMAC7.html)
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
PH12016500598A1 (en) Protoxin-ii variants and methods of use
PL2860256T3 (pl) Sposób wytwarzania L-aminokwasów
PH12016500497A1 (en) Compositions for the treatment of hypertension and/or fibrosis
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
EP3696190A3 (en) Methods
EA201690075A1 (ru) Способ лечения внутриклеточной инфекции
MX2016005545A (es) Analogo de la relaxina humana, composicion farmaceutica del mismo y aplicacion farmaceutica del mismo.
IN2013MU01113A (cg-RX-API-DMAC7.html)
MX2017013667A (es) Uso de un aditivo de combustible en combustible diesel para reducir el consumo de combustible en un motor diesel.
IL242911B (en) Tin-117m for treatment of immune, inflammatory and degenerative arthritides
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
MY173051A (en) Microorganism having producing ability of quinolinic acid and method for producing quinolinic acid using the microorganism
IN2013MU02486A (cg-RX-API-DMAC7.html)